<h2 dir="ltr"><strong>Graves Orbitopathy Overview</strong></h2>
<p dir="ltr">The most common non-thyroid complication of Graves' disease is Graves' Orbitopathy, which is caused by autoimmune activity leading to inflammation in the eye socket.</p>
<h3 dir="ltr"><strong>Graves Orbitopathy Epidemiology Segmentation</strong></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Total Sepsis Incidence cases</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Sepsis Gender-specific Incidence Cases</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Sepsis Severity-specific Incidence Cases</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Origin-specific Sepsis Incidence Cases</p>
</li>
</ul>
<h3 dir="ltr"><strong>Graves Orbitopathy Epidemiology&nbsp;</strong></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">There were around 7.1 million prevalent cases of Graves&rsquo; disease across the 7MM, with 3.5 million being diagnosed.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">In 2024, the US recorded the highest number of diagnosed prevalent cases of Graves&rsquo; orbitopathy</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">In 2024, the US reported nearly 122,000 diagnosed prevalent cases of Graves&rsquo; orbitopathy in males and 490,000 cases in females.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">In 2024, the EU4 and the UK reported nearly 195,000 acute cases and 503,000 chronic cases of Graves&rsquo; orbitopathy.</p>
</li>
</ul>
<h3 dir="ltr"><strong>Graves Orbitopathy Market</strong></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The total market size of Graves&rsquo; orbitopathy in the 7MM was approximately USD 2 billion in 2024 and is projected to increase during the forecast period (2025&ndash;2034).</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The market size for Graves&rsquo; orbitopathy in the US was approximately USD 1.9 billion in 2024 and is anticipated to increase due to the launch of emerging therapies.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Estimates suggest that veligrotug (VRDN-001) is expected to generate approximately USD 1,560 million in the 7MM by 2034.</p>
</li>
</ul>
<h3 dir="ltr"><strong>Graves Orbitopathy Market Drivers&nbsp;</strong></h3>
<p dir="ltr">Standardized tools like VISA and EUGOGO, alongside increased clinical awareness, are key to achieving an early diagnosis of Graves&rsquo; Orbitopathy, thereby allowing swift interventions to preempt severe disease progression.</p>
<h3 dir="ltr"><strong>Graves Orbitopathy Market Barriers</strong></h3>
<p dir="ltr">Due to its nature as a rare disease with a small patient base, challenges arise in clinical trial enrollment and, crucially, in establishing commercial viability, as large-scale investments are difficult to justify for a limited market.</p>
<h3 dir="ltr"><strong>Emerging Graves Orbitopathy Drugs</strong></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Veligrotug (VRDN-001)</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">VRDN-003</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Efgartigimod PH20 SC</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">ENSPRYNG (satralizumab; RG6168)</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Batoclimab (IMVT-1401; RVT-1401)</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Linsitinib</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Pacibekitug (TOUR006)</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">LASN01</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Lonigutamab, and others</p>
</li>
</ul>
<h3 dir="ltr"><strong>Key Graves Orbitopathy Companies</strong></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Amgen (Horizon Therapeutics)</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Viridian Therapeutics</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Argenx</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Tourmaline Bio, and others</p>
</li>
</ul>

Graves Orbitopathy Market Infographic | Treatment, Companies, Market Trends

Graves Orbitopathy Market Infographic

Graves Orbitopathy Market Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape